Ве молиме користете го овој идентификатор да го цитирате или поврзете овој запис:
http://hdl.handle.net/20.500.12188/18543
Наслов: | Should We Consider the Cardiovascular System While Evaluating CKD-MBD? | Authors: | Rroji, Merita Figurek, Andreja Spasovski, Goce |
Issue Date: | 2020 | Publisher: | MDPI AG | Journal: | Toxins | Abstract: | Cardiovascular (CV) disease is highly prevalent in the population with chronic kidney disease (CKD), where the risk of CV death in early stages far exceeds the risk of progression to dialysis. The presence of chronic kidney disease-mineral and bone disorder (CKD-MBD) has shown a strong correlation with CV events and mortality. As a non-atheromatous process, it could be partially explained why standard CV disease-modifying drugs do not provide such an impact on CV mortality in CKD as observed in the general population. We summarize the potential association of CV comorbidities with the older (parathyroid hormone, phosphate) and newer (FGF23, Klotho, sclerostin) CKD-MBD biomarkers. | URI: | http://hdl.handle.net/20.500.12188/18543 | DOI: | 10.3390/toxins12030140 |
Appears in Collections: | Faculty of Medicine: Journal Articles |
Files in This Item:
File | Опис | Size | Format | |
---|---|---|---|---|
should we consider.pdf | 1.25 MB | Adobe PDF | View/Open |
Page view(s)
19
checked on 1.5.2024
Download(s)
3
checked on 1.5.2024
Google ScholarTM
Проверете
Altmetric
Записите во DSpace се заштитени со авторски права, со сите права задржани, освен ако не е поинаку наведено.